Background and overview of application examples of 4-carboxy-2-chlorophenylboronic acid
4-Carboxy-2-chlorophenylboronic acid is a pharmaceutical intermediate that can be used for Suzuki coupling reactions. There are reports in the literature that it can be used to prepare CRF receptor antagonists and LXR and FXR modulators.
Application examples of 4-carboxy-2-chlorophenylboronic acid
Application examples of 4-carboxy-2-chlorophenylboronic acid Application 1,
CN99813171.7 reported that 4-carboxy-2-chlorophenylboronic acid can be used to prepare CRF receptor antagonists with the following similar structure. The CRF receptor antagonists of the present invention have broad therapeutic applications and can be used to treat various conditions or diseases, including stress-related conditions.
Application examples of 4-carboxy-2-chlorophenylboronic acid Application 2.
CN200780051148.6 reported that 4-carboxy-2-chlorophenylboronic acid can be used to prepare LXR and FXR modulators with the following similar structures. The nuclear receptors FXR and LX zinc carbonate hydroxide R are structurally related and closely related receptors. Furthermore, FXR and LXR play critical and functionally distinct roles in the coordinated control of bile acids, cholesterol, and triglycerides to maintain lipid homeostasis. Nuclear receptors and cholic acid/oxysterone-regulated genes are potential targets for the development of pharmaceutical hydroxypyridine therapies for lowering serum cholesterol and triglycerides and for the treatment of cardiovascular and liver diseases. Thus, compounds bearing the dual activity of LXR and FXR can have profound effects on lipid homeostasis and more effectively control disease conditions involving both FXR and LXR.
Application examples of 4-carboxy-2-chlorophenylboronic acid Application 3.
CN201080050922.3 reported that 4-carboxy-2-chlorophenylboronic acid can be used to prepare indole derivatives with the following structure, which can be used as NURR-1 activators for the treatment of Parkinson’s disease.
References
[1] [China invention, China invention authorization] CN200780051148.6 LXR and FXR regulator
[2] [China invention, China invention authorization] CN99813171.7 CRF receptor antagonist and methods related thereto
[3] [Invented in China] CN201080050922.3 Use of indole derivatives as NURR-1 activators as agents for treating Parkinson’s disease
